Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task forceCindy Strehl, Frank Buttgereit, N. Caeyers et al.|Annals of the Rheumatic Diseases|2016Cited by 331
2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseasesAnnette de Thurah, Christian Dejaco, Philipp Bösch et al.|Annals of the Rheumatic Diseases|2022Cited by 131